Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.47 |
| ▸ | VNN1 | O95497 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 3/20 | 0.39 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 9/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL353796 | 1.00 | RAB9A (0.47) | RAB9AVNN1KMT2AMEN1ALDH1A1 | |
| SCHEMBL366584 | 0.79 | CA1 (0.47) | RAB9AVNN1KMT2AMEN1ALDH1A1 | |
| SCHEMBL14012579 | 0.79 | CA1 (0.47) | RAB9AVNN1KMT2AMEN1ALDH1A1 | |
| SCHEMBL30961881 | 0.79 | CA1 (0.47) | RAB9AVNN1KMT2AMEN1ALDH1A1 | |
| SCHEMBL353795 | 0.78 | VNN1 (0.40) | VNN1ALDH1A1SMN1; SMN2CNR2 | |
| SCHEMBL14012595 | 0.77 | CYP11B1 (0.49) | RAB9AVNN1KMT2AMEN1ALDH1A1 | |
| SCHEMBL586822 | 0.77 | CYP11B1 (0.49) | RAB9AVNN1KMT2AMEN1ALDH1A1 | |
| SCHEMBL29896891 | 0.77 | CYP11B1 (0.49) | RAB9AVNN1KMT2AMEN1ALDH1A1 | |
| SCHEMBL3085415 | 0.77 | CYP11B2 (0.49) | VNN1CNR2 | |
| SCHEMBL15867031 | 0.77 | VNN1 (0.56) | VNN1ALDH1A1SMN1; SMN2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015957-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015957-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY1R, NPY5R | RAB9A 2225/4885VNN1 2522/4885KMT2A 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.